US Pharma MarketingPfizer ends Trillium-related development as R&D spend jumps
Pfizer has discontinued the final study stemming from the 2021 acquisition of Trillium Therapeutics, funneling cash primarily toward a barrage of other cancer and obesity studies. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and…
Pfizer has discontinued the final clinical study stemming from its 2021 acquisition of Trillium Therapeutics, funneling cash primarily toward a host of other cancer and obesity studies.
The company reported in
Source: Endpoints News